N-[3-acetyl-4-(5-chloropyridin-3-yl)oxyphenyl]-2,4-dichlorobenzenesulfonamide | 235427-32-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-[3-acetyl-4-(5-chloropyridin-3-yl)oxyphenyl]-2,4-dichlorobenzenesulfonamide
• CAS: 235427-32-4
• 化学式: C₁₉H₁₃Cl₃N₂O₄S
• 分子量: 471.748
• InChiKey: LALWWOHHASLXCM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  93.7
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-氯-5-硝基苯乙酮 在 吡啶 、 tin(II) chloride dihdyrate 、 caesium carbonate 作用下， 以 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-[3-acetyl-4-(5-chloropyridin-3-yl)oxyphenyl]-2,4-dichlorobenzenesulfonamide
  参考文献：
  名称：

  Discovery of INT131: A selective PPARγ modulator that enhances insulin sensitivity

  摘要：

  PPAR gamma is a member of the nuclear hormone receptor family and plays a key role in the regulation of glucose homeostasis. This Letter describes the discovery of a novel chemical class of diarylsulfonamide partial agonists that act as selective PPAR gamma modulators (SPPAR gamma Ms) and display a unique pharmacological profile compared to the thiazolidinedione (TZD) class of PPAR gamma full agonists. Herein we report the initial discovery of partial agonist 4 and the structure-activity relationship studies that led to the selection of clinical compound INT131 (3), a potent PPAR gamma partial agonist that displays robust glucose-lowering activity in rodent models of diabetes while exhibiting a reduced side-effects profile compared to marketed TZDs. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.11.058

文献信息

• US7439242B2
  申请人：——

  公开号：US7439242B2

  公开（公告）日：2008-10-21
• Discovery of INT131: A selective PPARγ modulator that enhances insulin sensitivity
  作者：Joshua P. Taygerly、Lawrence R. McGee、Steven M. Rubenstein、Jonathan B. Houze、Timothy D. Cushing、Yang Li、Alykhan Motani、Jin-Long Chen、Walter Frankmoelle、Guosen Ye、Marc R. Learned、Juan Jaen、Shichang Miao、Pieter B. Timmermans、Martin Thoolen、Patrick Kearney、John Flygare、Holger Beckmann、Jennifer Weiszmann、Michelle Lindstrom、Nigel Walker、Jinsong Liu、Donna Biermann、Zhulun Wang、Atsushi Hagiwara、Tetsuya Iida、Hisateru Aramaki、Yuki Kitao、Hisashi Shinkai、Noboru Furukawa、Jun Nishiu、Motonao Nakamura

  DOI：10.1016/j.bmc.2012.11.058

  日期：2013.2

  PPAR gamma is a member of the nuclear hormone receptor family and plays a key role in the regulation of glucose homeostasis. This Letter describes the discovery of a novel chemical class of diarylsulfonamide partial agonists that act as selective PPAR gamma modulators (SPPAR gamma Ms) and display a unique pharmacological profile compared to the thiazolidinedione (TZD) class of PPAR gamma full agonists. Herein we report the initial discovery of partial agonist 4 and the structure-activity relationship studies that led to the selection of clinical compound INT131 (3), a potent PPAR gamma partial agonist that displays robust glucose-lowering activity in rodent models of diabetes while exhibiting a reduced side-effects profile compared to marketed TZDs. (C) 2012 Elsevier Ltd. All rights reserved.